Hikma Pharmaceutic (HKMPF) Rating Lowered to Reduce at HSBC Holdings plc

Hikma Pharmaceutic (OTC:HKMPF) was downgraded by research analysts at HSBC Holdings plc from a “hold” rating to a “reduce” rating in a research note issued to investors on Friday, StockTargetPrices.com reports.

Hikma Pharmaceutic (OTC:HKMPF) opened at 26.50 on Friday. Hikma Pharmaceutic has a 52-week low of $20.43 and a 52-week high of $35.25. The firm’s 50-day moving average price is $25.26 and its 200 day moving average price is $24.41. The firm has a market cap of $5.99 billion and a PE ratio of 32.40.

var userip;Your IP Address: document.write(userip);

Stock Target Prices

Receive News & Ratings for Hikma Pharmaceutic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceutic and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Barclays Comes Up Short, Shares Fall
Barclays Comes Up Short, Shares Fall
Revenue at Twitter Beats the Street, Monthly Users Increase
Revenue at Twitter Beats the Street, Monthly Users Increase
McDonald’s Ordering Via Mobile Could Give Handsome Return
McDonald’s Ordering Via Mobile Could Give Handsome Return
Mattel CEO Promises Growth Following Sales Slump
Mattel CEO Promises Growth Following Sales Slump
Burberry Misses Estimates on Sales
Burberry Misses Estimates on Sales
Snapchat: CEO Did Not Label India as Being Poor
Snapchat: CEO Did Not Label India as Being Poor


© 2006-2017 Ticker Report. Google+.